Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ipratropium bromide delivered orally by metered dose inhaler does not decrease salivary flow in normal subjects.

V E Thomas1, F O'Connell, A J Harrison

  • 1Department of Clinical Pharmacology, Royal Postgraduate Medical School, London.

British Journal of Clinical Pharmacology
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A window of opportunity: tear cytokine profiles in chronic ocular graft-versus-host disease.

Eye (London, England)·2026
Same author

A Cure for Dandruff.

The Southern medical record·2022
Same author

Assessing the validity and sensitivity of microbial processes within a hydrodynamic model.

Water research·2022
Same author

Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour.

Digestive diseases and sciences·2022
Same author

Implications of bacterial mineralisation in aquatic ecosystem response models.

Water research·2021
Same author

Wastewater effluents cause microbial community shifts and change trophic status.

Water research·2021

This study found that ipratropium bromide (IPB) delivered via metered dose inhaler (MDI) did not significantly reduce saliva production in normal subjects. The drug

Area of Science:

  • Pharmacology
  • Oral Medicine
  • Drug Delivery Systems

Background:

  • Ipratropium bromide (IPB) is used for respiratory conditions.
  • Its potential effects on salivary secretion, particularly for hypersalivation, require investigation.
  • Metered dose inhalers (MDIs) are common drug delivery devices.

Purpose of the Study:

  • To evaluate the occurrence and duration of xerostomia (dry mouth) induced by IPB.
  • To assess the efficacy of oral IPB delivered via MDI for treating hypersalivation.

Main Methods:

  • A randomized, placebo-controlled, cross-over study.
  • Normal subjects received high (240 mcg) and low (120 mcg) doses of IPB via MDI.
  • Salivary output and palatability (Visual Analogue Scale) were measured.

Related Experiment Videos

Main Results:

  • Salivary output was not significantly reduced by either dose of IPB compared to placebo.
  • IPB was less palatable than placebo, potentially causing a reflex increase in saliva.
  • The drug's taste may have masked any local antisecretory effects.

Conclusions:

  • Oral IPB delivered by MDI is not a suitable treatment for hypersalivation.
  • Further research may be needed to explore alternative delivery methods or formulations.